Literature DB >> 9426077

Inhalation of dry-powder mannitol increases mucociliary clearance.

E Daviskas1, S D Anderson, J D Brannan, H K Chan, S Eberl, G Bautovich.   

Abstract

Inhalation of hypertonic saline stimulates mucociliary clearance (MCC) in healthy subjects and those with obstructive lung disease. We investigated the effect of inhaling the osmotic agent mannitol on MCC. We used a dry-powder preparation of mannitol British Pharmacopea (BP) which was encapsulated and delivered using a Dinkihaler. MCC was measured for 75 min in six asthmatic and six healthy subjects on two occasions before and after the mannitol inhalation or its control, using 99mTc-sulphur colloid and a gamma camera. The inhaled dose of mannitol was 267+/-171 mg (mean+/-SD) and 400 mg and the percentage fall in forced expiratory volume in one second (FEV1) was 22+/-3 and 4+/-2% in the asthmatic and healthy subjects, respectively. The total clearance in the whole right lung for the 60 min from the start of inhalation of mannitol was greater by 263+/-11.9% in the asthmatic and 18.1+/-4.9% in the healthy subjects compared to the control. The total clearance over 75 min was 54.7+/-9.6% and 33.6+/-9.4% on the mannitol and control day (p<0.002), respectively, in the asthmatic subjects and 40.5+/-7.1% and 24.8+/-7.8% (p<0.002) in the healthy subjects. In conclusion, inhalation of dry-powder mannitol increases mucociliary clearance in asthmatic and healthy subjects and may benefit patients with abnormal mucociliary clearance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9426077     DOI: 10.1183/09031936.97.10112449

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  13 in total

1.  Influence of particle size, air flow, and inhaler device on the dispersion of mannitol powders as aerosols.

Authors:  N Y Chew; H K Chan
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

2.  Hyper-osmolarity and calcium chelation: Effects on cystic fibrosis mucus.

Authors:  Anna Ermund; Lauren N Meiss; Jenny K Gustafsson; Gunnar C Hansson
Journal:  Eur J Pharmacol       Date:  2015-06-30       Impact factor: 4.432

Review 3.  Mannitol dry powder for inhalation: in patients with cystic fibrosis.

Authors:  Celeste B Burness; Gillian M Keating
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 4.  New pulmonary therapies directed at targets other than CFTR.

Authors:  Scott H Donaldson; Luis Galietta
Journal:  Cold Spring Harb Perspect Med       Date:  2013-06-01       Impact factor: 6.915

Review 5.  Mucus, mucins, and cystic fibrosis.

Authors:  Cameron Bradley Morrison; Matthew Raymond Markovetz; Camille Ehre
Journal:  Pediatr Pulmonol       Date:  2019-11

Review 6.  Hypertonic saline in treatment of pulmonary disease in cystic fibrosis.

Authors:  Emer P Reeves; Kevin Molloy; Kerstin Pohl; Noel G McElvaney
Journal:  ScientificWorldJournal       Date:  2012-05-03

Review 7.  Inhaled mannitol for cystic fibrosis.

Authors:  Sarah J Nevitt; Judith Thornton; Clare S Murray; Tiffany Dwyer
Journal:  Cochrane Database Syst Rev       Date:  2018-02-09

8.  Safety assessment of inhaled xylitol in mice and healthy volunteers.

Authors:  Lakshmi Durairaj; Janice Launspach; Janet L Watt; Thomas R Businga; Joel N Kline; Peter S Thorne; Joseph Zabner
Journal:  Respir Res       Date:  2004-09-16

9.  Inhaled mannitol for cystic fibrosis.

Authors:  Sarah J Nevitt; Judith Thornton; Clare S Murray; Tiffany Dwyer
Journal:  Cochrane Database Syst Rev       Date:  2020-05-01

10.  A comparative study of lidocaine and lidocaine- mannitol in anesthetizing human teeth with inflamed pulps.

Authors:  Ali Talati; Maryam Bidar; Ghazal Sadeghi; Hossein Nezami
Journal:  Iran Endod J       Date:  2006-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.